TEVA-LIOTHYRONINE TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

LIOTHYRONINE (LIOTHYRONINE SODIUM)

Commercializzato da:

TEVA CANADA LIMITED

Codice ATC:

H03AA02

INN (Nome Internazionale):

LIOTHYRONINE SODIUM

Dosaggio:

25MCG

Forma farmaceutica:

TABLET

Composizione:

LIOTHYRONINE (LIOTHYRONINE SODIUM) 25MCG

Via di somministrazione:

ORAL

Confezione:

15G/50G

Tipo di ricetta:

Prescription

Area terapeutica:

THYROID AGENTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0102421002; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2019-11-21

Scheda tecnica

_ _
_Teva-Liothyronine Tablets _
_Page 1 of 17_
PRODUCT MONOGRAPH
Pr
TEVA-LIOTHYRONINE
Liothyronine Sodium Tablets
5 mcg and 25 mcg liothyronine as liothyronine sodium
USP
Hypothyroidism Therapy
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Approval:
November 20, 2019
Submission Control No: 217318
_ _
_Teva-Liothyronine Tablets _
_Page 2 of 17_
TABLE OF CONTENTS
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DRUG/LABORATORY TEST INTERACTIONS
.............................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION
............................................................................................................................12
CLINICAL PHARMACOLOGY
......................................................................................12
SUPPLY
.............................................................................................................................15
COMPOSITION
................................................................................................................15
PART III: CONSUMER INFORMATION
......................................................................16
_ _
_Teva-Liothyronine Tablets _
_Page 3 of 17_
Pr
TEVA-LIOTHYRONINE
liothyronine sodium
INDICATIONS AND CLINICAL USE
TEVA-LIOTHYRONINE is